Meta-analysis of influences of Biejiajian Pill combined with entecavir on serum liver fibrosis markers of compensatory period of hepatitis b cirrhosis: Protocol of systematic review and meta-analysis.

Abstract

BACKGROUND:

Chronic viral hepatitis b and its related complications have caused serious harm to human health and become a worldwide public health problem. Hepatitis b cirrhosis is one of the most common complications in Asia. Traditional Chinese medicine combined with antiviral therapy has become the first choice for clinical treatment of hepatitis b Cirrhosis. Biejia Pill is an effective prescription of traditional Chinese medicine in treating Compensatory period of cirrhosis, and there are more and more clinical reports about its validity in treating Compensatory period of cirrhosis. Therefore, we designed this study protocol to evaluate the adjuvant role of Biejia Pill in the treatment of Compensatory period of cirrhosis.

METHOD:

Electronic Databases, PubMed, EMBASE database, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wan Fang, Chinese Scientific Journals Database (VIP) and China Biology Medicine disc, (CBM), will be systematically searched from inception to July 2019. Randomized controlled trials (RCTs) on Biejiajian Pill combined with Entecavir and Entecavir alone against Compensatory period of hepatitis b cirrhosis will be included; inclusion and exclusion criteria will be used to screen the trials. liver fibrosis biomarkers including ECM or its metabolites (serum hyaluronic acid (HA), laminin (LN), procollagen type III (PC-III), and type IV collagen (IV-C)) will be measured as primary outcomes. Liver function, including alanine aminotransferase (ALT) and aspartarte aminotransferase (AST), and improvement of related clinical symptoms will be measured as secondary outcomes. RevMan5 software will be used for literature quality evaluation and data synthesis and analysis.

RESULT:

To evaluate the efficacy and safety of Biejiajian Pill in combination therapy by observing the outcomes of serum liver fibrosis markers, adverse reactions and liver function.

CONCLUSION:

This study protocol will be used to evaluate the efficacy and safety of Biejia Pill in combination with entecavir in the treatment of Compensatory period of hepatitis b cirrhosis, as well as the adjuvant treatment of Biejia Pill in combination.PROSPERO registration number: CRD42019135402.

• Authors: Tianyao Zhang, Yu Yang, Baojia Wang, Xiuli Zheng, Long Wang, Xianrong Feng, Guiyu Li, Jinyu Shi, Ning Cao
• Journal: Medicine (Medicine (Baltimore)) Vol. 98 Issue 51 Pg. e18458 (Dec 2019) ISSN: 1536-5964 [Electronic] United States
• PMID: 31861022 (Publication Type: Journal Article, Meta-Analysis)

Chemical References

• Antiviral Agents
• Biomarkers
• Drugs, Chinese Herbal
• bie jia jian
• entecavir
• Guanine

Topics

• Antiviral Agents (therapeutic use)
• Biomarkers (blood)
• Drug Therapy, Combination
• Drugs, Chinese Herbal (therapeutic use)
• Guanine (analogs & derivatives, therapeutic use)
• Hepatitis B (complications)
• Humans
• Liver Cirrhosis (blood, drug therapy, etiology, virology)
• Systematic Reviews as Topic